JP2019505598A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505598A5
JP2019505598A5 JP2018563402A JP2018563402A JP2019505598A5 JP 2019505598 A5 JP2019505598 A5 JP 2019505598A5 JP 2018563402 A JP2018563402 A JP 2018563402A JP 2018563402 A JP2018563402 A JP 2018563402A JP 2019505598 A5 JP2019505598 A5 JP 2019505598A5
Authority
JP
Japan
Prior art keywords
configuration
day
level
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/019094 external-priority patent/WO2017147276A1/en
Publication of JP2019505598A publication Critical patent/JP2019505598A/ja
Publication of JP2019505598A5 publication Critical patent/JP2019505598A5/ja
Pending legal-status Critical Current

Links

JP2018563402A 2016-02-23 2017-02-23 Smad7の阻害を用いて、腸線維症を治療する方法 Pending JP2019505598A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298988P 2016-02-23 2016-02-23
US62/298,988 2016-02-23
PCT/US2017/019094 WO2017147276A1 (en) 2016-02-23 2017-02-23 Methods of treating intestinal fibrosis using smad7 inhibition

Publications (2)

Publication Number Publication Date
JP2019505598A JP2019505598A (ja) 2019-02-28
JP2019505598A5 true JP2019505598A5 (cg-RX-API-DMAC7.html) 2020-04-16

Family

ID=59686543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563402A Pending JP2019505598A (ja) 2016-02-23 2017-02-23 Smad7の阻害を用いて、腸線維症を治療する方法

Country Status (4)

Country Link
US (1) US11162097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3420082A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019505598A (cg-RX-API-DMAC7.html)
WO (1) WO2017147276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
CN108753791B (zh) * 2018-07-01 2020-10-13 中国农业科学院植物保护研究所 绿盲蝽decapentaplegic基因及其RNAi在害虫防控中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
JP6301844B2 (ja) * 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US9078918B2 (en) * 2012-05-08 2015-07-14 Northwestern University Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
DK2948137T3 (en) * 2013-01-18 2019-01-07 Genfit METHODS OF TREATING FIBROSE AND CANCER TYPES
EP2970419B8 (en) 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US20170247695A1 (en) 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US20180289692A1 (en) 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
AU2016360956A1 (en) * 2015-11-25 2018-06-07 Nogra Pharma Limited IL-34 antisense oligonucleotides and methods of using same
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
JP2019507755A (ja) 2016-02-24 2019-03-22 ノグラ ファーマ リミテッド Smad7阻害を使用するセリアック病の処置の方法
US20200237801A1 (en) 2016-05-12 2020-07-30 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
JP2020528910A (ja) 2017-07-28 2020-10-01 セルジーン コーポレイション オリゴヌクレオチド化合物の調製方法

Similar Documents

Publication Publication Date Title
Hanania Targeting airway inflammation in asthma: current and future therapies
Hammers et al. Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle
JP2017537973A5 (cg-RX-API-DMAC7.html)
Jahansouz et al. Sleeve gastrectomy drives persistent shifts in the gut microbiome
JP2018531936A5 (cg-RX-API-DMAC7.html)
MD4327866T2 (ro) Mirikizumab în tratarea colitei ulcerative
JP2019507755A5 (cg-RX-API-DMAC7.html)
US20180180630A1 (en) Methods for treating inflammatory bowel disease
CN105358150A (zh) 用于心脏病的bet抑制疗法
Donkervoort et al. Mosaicism for dominant collagen 6 mutations as a cause for intrafamilial phenotypic variability
KR20170031245A (ko) 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물
CA2962944A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
JP2025143437A (ja) ヒト対象者における心不全の治療
JP2019519544A5 (cg-RX-API-DMAC7.html)
JP2022529929A5 (cg-RX-API-DMAC7.html)
CA2971583A1 (en) Methods of using smad7 antisense oligonucleotides
CN111630168B (zh) 治疗心力衰竭的改良化合物
Lattuada et al. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes
WO2013088853A1 (ja) オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター
EP3380615B1 (en) Il-34 antisense oligonucleotides and methods of using same
US20100105762A1 (en) Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
WO2013036998A1 (en) Treatment of bone diseases
Kameda et al. Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
US20170136089A1 (en) Compositions and methods of regulating bone resorption
WO2017147276A1 (en) Methods of treating intestinal fibrosis using smad7 inhibition